BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vairy S, Garcia JL, Teira P, Bittencourt H. CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia. Drug Des Devel Ther 2018;12:3885-98. [PMID: 30518999 DOI: 10.2147/DDDT.S138765] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Stock W, Martinelli G, Stelljes M, DeAngelo DJ, Gökbuget N, Advani AS, O'Brien S, Liedtke M, Merchant AA, Cassaday RD, Wang T, Zhang H, Vandendries E, Jabbour E, Marks DI, Kantarjian HM. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer 2021;127:905-13. [PMID: 33231879 DOI: 10.1002/cncr.33321] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
2 Vanhooren J, Derpoorter C, Depreter B, Deneweth L, Philippé J, De Moerloose B, Lammens T. TARP as antigen in cancer immunotherapy. Cancer Immunol Immunother 2021. [PMID: 34050774 DOI: 10.1007/s00262-021-02972-x] [Reference Citation Analysis]
3 Santamaria-Alza Y, Vasquez G. Are chimeric antigen receptor T cells (CAR-T cells) the future in immunotherapy for autoimmune diseases? Inflamm Res 2021;70:651-63. [PMID: 34018005 DOI: 10.1007/s00011-021-01470-1] [Reference Citation Analysis]
4 Su FY, Mac QD, Sivakumar A, Kwong GA. Interfacing Biomaterials with Synthetic T Cell Immunity. Adv Healthc Mater 2021;10:e2100157. [PMID: 33887123 DOI: 10.1002/adhm.202100157] [Reference Citation Analysis]
5 De Bousser E, Callewaert N, Festjens N. T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy. Cancers (Basel) 2021;13:6067. [PMID: 34885176 DOI: 10.3390/cancers13236067] [Reference Citation Analysis]
6 Xie M, Viviani M, Fussenegger M. Engineering precision therapies: lessons and motivations from the clinic. Synth Biol (Oxf) 2021;6:ysaa024. [PMID: 33817342 DOI: 10.1093/synbio/ysaa024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Dana H, Chalbatani GM, Jalali SA, Mirzaei HR, Grupp SA, Suarez ER, Rapôso C, Webster TJ. CAR-T cells: Early successes in blood cancer and challenges in solid tumors. Acta Pharm Sin B 2021;11:1129-47. [PMID: 34094824 DOI: 10.1016/j.apsb.2020.10.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Motais B, Charvátová S, Hrdinka M, Šimíček M, Jelínek T, Ševčíková T, Kořístek Z, Hájek R, Bagó JR. A Bird's-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers. Cancers (Basel) 2020;12:E1333. [PMID: 32456165 DOI: 10.3390/cancers12051333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Zhang Y, Wang N, Ding M, Yang Y, Wang Z, Huang L, Zhu W, Mellor AL, Hou X, Zhou C, Yan R, Wang W, Wu S. CD40 Accelerates the Antigen-Specific Stem-Like Memory CD8+ T Cells Formation and Human Papilloma Virus (HPV)-Positive Tumor Eradication. Front Immunol 2020;11:1012. [PMID: 32536922 DOI: 10.3389/fimmu.2020.01012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Ho KW, Chen IU, Cheng YA, Liao TY, Liu ES, Chen HJ, Lu YC, Su YC, Roffler SR, Huang BC, Liu HJ, Huang MY, Chen CY, Cheng TL. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity. J Nanobiotechnology 2021;19:16. [PMID: 33422061 DOI: 10.1186/s12951-020-00752-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Awasthi R, Pacaud L, Waldron E, Tam CS, Jäger U, Borchmann P, Jaglowski S, Foley SR, van Besien K, Wagner-Johnston ND, Kersten MJ, Schuster SJ, Salles G, Maziarz RT, Anak Ö, Del Corral C, Chu J, Gershgorin I, Pruteanu-Malinici I, Chakraborty A, Mueller KT, Waller EK. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv 2020;4:560-72. [PMID: 32045475 DOI: 10.1182/bloodadvances.2019000525] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 31.0] [Reference Citation Analysis]
12 Yang X, Wang GX, Zhou JF. CAR T Cell Therapy for Hematological Malignancies. Curr Med Sci 2019;39:874-82. [PMID: 31845217 DOI: 10.1007/s11596-019-2118-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
13 Wang F, Wang F, Zhang S, Xu X. MicroRNA-325 inhibits the proliferation and induces the apoptosis of T cell acute lymphoblastic leukemia cells in a BAG2-dependent manner. Exp Ther Med 2021;21:631. [PMID: 33936287 DOI: 10.3892/etm.2021.10063] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Park JH, Seo JH, Jeon HY, Seo SM, Lee HK, Park JI, Kim JY, Choi YK. Lentivirus-Mediated VEGF Knockdown Suppresses Gastric Cancer Cell Proliferation and Tumor Growth in vitro and in vivo. Onco Targets Ther 2020;13:1331-41. [PMID: 32104000 DOI: 10.2147/OTT.S234344] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Mühlberger M, Janko C, Unterweger H, Friedrich RP, Friedrich B, Band J, Cebulla N, Alexiou C, Dudziak D, Lee G, Tietze R. Functionalization Of T Lymphocytes With Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles For Magnetically Controlled Immune Therapy. Int J Nanomedicine 2019;14:8421-32. [PMID: 31749616 DOI: 10.2147/IJN.S218488] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 5.3] [Reference Citation Analysis]
16 Liang Z, Cui J, Chang AH, Yu J, Hu Y, Huang H. Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy. Regen Ther 2020;15:281-4. [PMID: 33426230 DOI: 10.1016/j.reth.2020.11.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione C. A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia. Int J Mol Sci 2021;22:2150. [PMID: 33670075 DOI: 10.3390/ijms22042150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Hu X, Chen R, Wei Q, Xu X. The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We? Int J Biol Sci 2022;18:536-51. [PMID: 35002508 DOI: 10.7150/ijbs.64537] [Reference Citation Analysis]
19 Lundstrom K. RNA Viruses as Tools in Gene Therapy and Vaccine Development. Genes (Basel) 2019;10:E189. [PMID: 30832256 DOI: 10.3390/genes10030189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
20 Allegra A, Gioacchino MD, Tonacci A, Petrarca C, Gangemi S. Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective. Nanomaterials (Basel) 2021;11:2792. [PMID: 34835555 DOI: 10.3390/nano11112792] [Reference Citation Analysis]
21 Derdelinckx J, Reynders T, Wens I, Cools N, Willekens B. Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD. Int J Mol Sci 2021;22:7925. [PMID: 34360690 DOI: 10.3390/ijms22157925] [Reference Citation Analysis]
22 Watanabe N, Mo F, Mckenna MK. Impact of Manufacturing Procedures on CAR T Cell Functionality. Front Immunol 2022;13:876339. [DOI: 10.3389/fimmu.2022.876339] [Reference Citation Analysis]
23 Bezeljak U. Cancer gene therapy goes viral: viral vector platforms come of age. Radiol Oncol 2022;56:1-13. [PMID: 35148469 DOI: 10.2478/raon-2022-0002] [Reference Citation Analysis]
24 Anderson LD Jr. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Future Oncol 2022;18:277-89. [PMID: 34854741 DOI: 10.2217/fon-2021-1090] [Reference Citation Analysis]
25 Enriquez-Ochoa D, Robles-Ovalle P, Mayolo-Deloisa K, Brunck MEG. Immobilization of Growth Factors for Cell Therapy Manufacturing. Front Bioeng Biotechnol 2020;8:620. [PMID: 32637403 DOI: 10.3389/fbioe.2020.00620] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
26 Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol 2021;18:71-84. [PMID: 32978608 DOI: 10.1038/s41571-020-0427-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
27 Nagree MS, Felizardo TC, Faber ML, Rybova J, Rupar CA, Foley SR, Fuller M, Fowler DH, Medin JA. Autologous, lentivirus-modified, T-rapa cell "micropharmacies" for lysosomal storage disorders. EMBO Mol Med 2022;:e14297. [PMID: 35298086 DOI: 10.15252/emmm.202114297] [Reference Citation Analysis]
28 Buechner J, Caruana I, Künkele A, Rives S, Vettenranta K, Bader P, Peters C, Baruchel A, Calkoen FG. Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant? Front Pediatr 2022;9:784024. [DOI: 10.3389/fped.2021.784024] [Reference Citation Analysis]
29 Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev 2019;38:573-94. [PMID: 31828566 DOI: 10.1007/s10555-019-09819-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
30 Skorka K, Ostapinska K, Malesa A, Giannopoulos K. The Application of CAR-T Cells in Haematological Malignancies. Arch Immunol Ther Exp (Warsz) 2020;68:34. [PMID: 33156409 DOI: 10.1007/s00005-020-00599-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Zhao L, Cao YJ. Engineered T Cell Therapy for Cancer in the Clinic. Front Immunol 2019;10:2250. [PMID: 31681259 DOI: 10.3389/fimmu.2019.02250] [Cited by in Crossref: 81] [Cited by in F6Publishing: 71] [Article Influence: 27.0] [Reference Citation Analysis]
32 Macpherson AM, Barry SC, Ricciardelli C, Oehler MK. Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy. JCM 2020;9:2967. [DOI: 10.3390/jcm9092967] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
33 Ahmad A, Uddin S, Steinhoff M. CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas. Int J Mol Sci 2020;21:E3906. [PMID: 32486160 DOI: 10.3390/ijms21113906] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 9.5] [Reference Citation Analysis]
34 Lejman M, Kuśmierczuk K, Bednarz K, Ostapińska K, Zawitkowska J. Targeted Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia-Therapy and Toxicity Mechanisms. Int J Mol Sci 2021;22:9827. [PMID: 34575992 DOI: 10.3390/ijms22189827] [Reference Citation Analysis]